Related posts
Most Anticipated Earnings: SLF-T, REAL-T and more Canadian Companies Reporting Earnings this Week (Nov 13-17)Stocks and gold climbFedEx warning chills marketsThis summary was created by AI, based on 3 opinions in the last 12 months.
Overall, the experts have a negative outlook on Aurora Cannabis, citing high risk and speculation within the sector. They do not foresee any catalysts to drive the sector higher, especially with potential political changes in the US. Additionally, the economic factors surrounding the growth of weed pose challenges, and the experts believe that the real opportunity will come with federal legalization in the US. While the company has some presence in Europe, it is not considered to have the strongest assets. Ultimately, the experts favor other companies, particularly MSOs, over Aurora Cannabis.
The problem is that parts of the world weed grows easily, so the economics don't work. The big opportunity will happen when the US legalizes weed federal, then weed shares will pop. If you're under water this, take the tax loss.
Look at what the opportunity is. The US has increased medical and recreational use, plus favourable legislation. Doesn't have the strongest set of assets in the US, so he'd favour MSOs over ACB. Europe is the longer-range opportunity, where it has a foothold.
They each have their own strengths. He would pick Canopy (WEED-T) because they are the 800 lb gorilla. Aurora has lots of news about balance sheet challenges but they have low costs that he thinks will still come down further.
His weed exposure is through Constellation Brands which owns Canopy--this is less risky than owning cannabis stocks. The valuation on the entire sector rose way too high in 2017-8. Now, the industry is feeling growing pains, with unexpected surprises in working with governments. Generally sin stocks do well long term, but the next year or two will be challenging.
Aurora Cannabis is a Canadian stock, trading under the symbol ACB-T on the Toronto Stock Exchange (ACB-CT). It is usually referred to as TSX:ACB or ACB-T
In the last year, 2 stock analysts published opinions about ACB-T. 0 analysts recommended to BUY the stock. 2 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Aurora Cannabis.
Aurora Cannabis was never recommended as a Top Pick on Stockchase. Read the latest stock experts ratings for Aurora Cannabis.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
2 stock analysts on Stockchase covered Aurora Cannabis In the last year. It is a trending stock that is worth watching.
On 2024-09-20, Aurora Cannabis (ACB-T) stock closed at a price of $7.77.
Avoid the sector. High risk, speculative. Doesn't see catalysts to drive the sector higher, especially if Republicans succeed in the US election.